Key facts
- This page summarizes Angela Hu's Form 3 filing for XBiotech Inc. (XBIT).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 23 Feb 2023, 13:51.
Angela Hu - 10 Feb 2023 Form 3 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Principle Financial Officer
- Issuer ticker
- XBIT
- Reported as of
- 10 Feb 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Angela Hu
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Angela Hu filed Form 3 for XBiotech Inc. (XBIT) on 23 Feb 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XBIT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,500
- Date
- 10 Feb 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XBIT
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,500
- Exercise price
- $19.00
- Footnotes
- F1
XBIT
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $5.26
- Footnotes
- F2
XBIT
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $10.36
- Footnotes
- F3
XBIT
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $12.67
- Footnotes
- F4
XBIT
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $3.84
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On April 1, 2015 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in four years commencing as of April 1, 2016, with an expiry of ten years from the Grant Date.
Footnote F2
On January 4, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of January 4, 2020, with an expiry of ten years from the Grant Date.
Footnote F3
On November 6, 2019 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 6, 2020, with an expiry of ten years from the Grant Date.
Footnote F4
On November 19, 2021 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions in two years commencing as of November 19, 2022, with an expiry of ten years from the Grant Date.
Footnote F5
On February 10, 2023 (the Grant Date) the reporting person was granted stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in four equal portions in two years commencing as of August 10, 2023, with an expiry of ten years from the Grant Date.